Pharma News

Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.

Valeant Pharmaceuticals and EyeGate Enter into Licensing Agreement for EGP-437 Combination Product

Wednesday, February 22, 2017

Valeant Pharmaceuticals International Inc and EyeGate Pharmaceuticals Inc a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye today announced that they have entered into an exclusive worldwide licensing agreement t..

AMRI Entered into an Agreement with Ferrer and Accord Healthcare

Wednesday, February 22, 2017

AMRI announced that it has entered into an agreement with the pharmaceutical group Ferrer and Accord Healthcare Inc Accord Healthcare to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the opti..

FDA rejects Amphastar's nasal opioid overdose treatment

Wednesday, February 22, 2017

Amphastar Pharmaceuticals Inc said on Tuesday that the US Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioidoverdose treatment naloxone The abuse of opioids a class of drugs that includes heroin and prescription painkillers has assu..

ICON Selected by the FDA to Validate Patient-Reported Outcome Endpoints for Antibacterial Drug Trials

Tuesday, February 21, 2017

ICON plc a global provider of drug development solutions and services to the pharmaceutical biotechnology and medical device industries today announced that it has been awarded a project by the US Food Drug Administration FDA to validate three Patient Reported Outcomes PRO instruments that will mea..

Xbrane Biopharma obtains GMP certification for Spherotide production facility

Tuesday, February 21, 2017

Xbrane Biopharma has been granted GMP Good Manufacturing Practice certification for its Spherotide production facility by AIFA the Italian Medicines Agency The GMP certification follows an inspection by AIFA where the production facility was found to demonstrate compliance with GMP standards The GMP..

Immune Pharmaceuticals Announces the launch of REMAIN™

Monday, February 20, 2017

Immune Pharmaceuticals Inc will announce on Monday February 20th 2017 at the Acute Leukemia XVI symposium in Munich Germany that it will be launching REMAIN an international Overall Survival clinical study with the combination of Ceplene the Company39s flagship product for Acute Myeloid Leukemia AML..

CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement

Monday, February 20, 2017

Today CanniMed Therapeutics Inc and CTT Pharmaceutical Holdings Inchave entered into a definitive contractual relationship for the licensing of CTTs Orally Dissolvable Thin Film ODF Wafer technology This industryfirst collaboration includes the licensing of six patents related to cannabinoid and ..

Health Canada Approves Otsuka and Lundbeck's REXULTI™

Saturday, February 18, 2017

Otsuka Pharmaceutical Co Ltd and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI brexpiprazole for the treatment of schizophrenia in adults REXULTI was discovered by Otsuka and codeveloped with Lundbeck It will be comarketed by the two companies and is expected ..

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

Friday, February 17, 2017

Imprimis Pharmaceuticals Incan ophthalmologyfocused pharmaceutical company today announced that it has begun shipping its core sterile ophthalmic medications to select customers from its FDAregistered outsourcing facility without the need for a patientspecific prescription Over the next few weeks Im..

Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Friday, February 17, 2017

Dauntless Pharmaceuticals Inc a privately held biopharmaceutical company focused on the development of specialty therapeutics today announced the initiation of a Phase 1 clinical study to assess the safety tolerability pharmacokinetics and pharmacodynamics of DP1038 a novel formulation of octreotide..